Holen Sie sich die Stockscreener-App
64.26
1.28%
0.81
Handel nachbörslich:
64.26
Schlusskurs vom Vortag:
$63.45
Offen:
$63.88
24-Stunden-Volumen:
1.24M
Relative Volume:
0.72
Marktkapitalisierung:
$13.13B
Einnahmen:
$2.75B
Nettoeinkommen (Verlust:
$322.29M
KGV:
83.60
EPS:
0.7687
Netto-Cashflow:
$300.88M
1W Leistung:
+1.32%
1M Leistung:
-8.89%
6M Leistung:
-15.95%
1J Leistung:
-27.32%
1-Tages-Spanne:
$63.78
$64.46
1-Wochen-Bereich:
$61.15
$64.46
52-Wochen-Spanne:
$61.15
$99.56
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Firmenname
Biomarin Pharmaceutical Inc
Sektor
Branche
Telefon
(415) 506-6700
Adresse
105 DIGITAL DRIVE, NOVATO, CA
Vergleichen Sie BMRN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| BMRN | 64.26 | 13.13B | 2.75B | 322.29M | 300.88M | 0.7687 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-20 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-17 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-14 | Eingeleitet | Evercore ISI | Outperform |
| 2023-11-15 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-23 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-09-28 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-09-18 | Eingeleitet | UBS | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-07-05 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Underperform |
| 2023-02-22 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2023-02-21 | Eingeleitet | Citigroup | Neutral |
| 2023-01-30 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2022-10-31 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-13 | Fortgesetzt | Wedbush | Neutral |
| 2022-04-25 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2021-11-22 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-09-09 | Hochstufung | Stifel | Hold → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-04 | Fortgesetzt | Guggenheim | Buy |
| 2021-03-01 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2020-08-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-08-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-08-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2020-08-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-08-19 | Herabstufung | Stifel | Buy → Hold |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-06 | Bestätigt | Citigroup | Buy |
| 2020-01-28 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-27 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2020-01-24 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2019-11-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-04-09 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-12-14 | Eingeleitet | Wolfe Research | Outperform |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-07 | Bestätigt | Stifel | Buy |
| 2018-08-03 | Bestätigt | Stifel | Buy |
Alle ansehen
Biomarin Pharmaceutical Inc Aktie (BMRN) Neueste Nachrichten
King Luther Capital Management Corp Makes New Investment in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Connor Clark & Lunn Investment Management Ltd. Invests $8.17 Million in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Can BioMarin Stock Live Up to Wall Street’s High Expectations? - sharewise
What is Zacks Research's Forecast for BMRN FY2024 Earnings? - MarketBeat
Can BioMarin Stock Live Up to Wall Street's High Expectations? - Benzinga
Why Is BioMarin Pharmaceutical Inc. (BMRN) Among the Worst Performing Biotech Stocks in 2024? - Yahoo Finance
Layoff Tracker: J&J, Merck Trimming Workforces in China - BioSpace
BioMarin: Challenges Mount, But Sale Rumors Make For A Risky 'Buy' Call (NASDAQ:BMRN) - Seeking Alpha
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance
Zacks Research Brokers Raise Earnings Estimates for BMRN - MarketBeat
Primecap Management Co. CA Acquires 77,350 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Phenylketonuria Market size is ~700 USD million in 2023, asserts DelveInsight | Pharma Giants: PTC Therapeutics, Homology Medicines, Synlogic, BioMarin Pharmaceuticals - The Globe and Mail
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - Yahoo Finance
EULAV Asset Management Grows Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Wolfe Research Initiates Coverage of BioMarin Pharmaceutical (BMRN) with Outperform Recommendation - MSN
Howe & Rusling Inc. Acquires 24,971 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (BMRN): Among the Best Genomics Stocks to Buy Right Now - Insider Monkey
Implied Volatility Surging for BioMarin Pharmaceutical (BMRN) Stock Options - MSN
10 Biggest Biotechnology Companies - Investopedia
Sumitomo Mitsui Trust Group Inc. Has $32.06 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Presents Real-World Evidence Further Supporting Safety and Efficacy of VOXZOGO® (vosoritide) in Children with Achondroplasia at the European Society for Paediatric Endocrinology (ESPE) Meeting 2024 - Kilgore News Herald
Comgest Global Investors S.A.S. Trims Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Los Angeles Capital Management LLC Acquires New Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin stock touches 52-week low at $65.23 amid challenges - Investing.com India
BioMarin Pharmaceutical (NASDAQ:BMRN) Hits New 1-Year Low on Insider Selling - MarketBeat
BioMarin Pharmaceutical (NASDAQ:BMRN) Now Covered by Analysts at Wolfe Research - MarketBeat
Biomarin pharmaceutical's CTO sells $350k in stock By Investing.com - Investing.com Nigeria
Biomarin pharmaceutical's CTO sells $350k in stock - Investing.com India
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Not Flying Under The Radar - Simply Wall St
WCM Investment Management LLC Has $1.20 Million Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
abrdn Life Sciences Investors declares $0.50 dividend - MSN
Principal Financial Group Inc. Sells 191,421 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
How To Trade (BMRN) - Stock Traders Daily
National Pension Service Grows Stock Holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Here’s Why BioMarin Aristotle Large Cap Growth Strategy Divested From Pharmaceutical (BMRN) - Insider Monkey
Robeco Institutional Asset Management B.V. Buys 128,807 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin to Participate in Three Upcoming Investor Conferences - StockTitan
BioMarin Pharmaceutical (NASDAQ:BMRN) Upgraded at Wedbush - MarketBeat
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - MSN
BioMarin Pharmaceutical Inc.: Enhancement of Enzyme Replacement Therapy (ERT) Portfolio - Smartkarma
CAMP4 Analyst Highlights Rare Disease Platform Potential - Benzinga
BioMarin's SWOT analysis: rare disease biotech stock faces growth challenges - Investing.com
AlphaCentric Advisors LLC Purchases 16,000 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In - MSN
Is BioMarin (BMRN) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
BioMarin (BMRN) Upgraded to Buy: Here's Why - Yahoo Finance UK
BMRN vs. INCY: Which Stock Is the Better Value Option? - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term - Yahoo Finance
FY2024 Earnings Forecast for BMRN Issued By Leerink Partnrs - MarketBeat
F M Investments LLC Buys New Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - MarketBeat
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Finanzdaten der Biomarin Pharmaceutical Inc-Aktie (BMRN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
2.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):